AUTHOR=Cheung Peter P. 

TITLE=Anti-IL17A in Axial Spondyloarthritis—Where Are We At?

JOURNAL=Frontiers in Medicine

VOLUME=4

YEAR=2017

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2017.00001

DOI=10.3389/fmed.2017.00001

ISSN=2296-858X

ABSTRACT=<p>Knowledge regarding the mechanisms of the IL17–IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis. Clinical studies and current issues surrounding the use of secukinumab will be discussed.</p>